Abstract:Ethnopharmacological relevance Radix Glycyrrhizae (GL), an herbal medicine that is widely available, has shown advantages for a variety of inflammatory diseases. Toll like receptor 4 (TLR4) pathway has been shown to play a key role in the progression of inflammation. Aim of the study The purpose of this study was to investigate the involvement of TLR4 in the anti-inflammatory mechanism of GL extract and its active constituent on acute lung injury (ALI). Materials and methods A model of inflammation produced by lipopolysaccharide (LPS) was established in C57BL/6 mice and macrophages derived from THP-1. To screen the active components of GL, molecular docking was used. Molecular dynamics and surface plasmon resonance imaging (SPRi) were used to study the interaction of a specific drug with the TLR4-MD2 complex. TLR4 was overexpressed by adenovirus to confirm TLR4 involvement in the anti-inflammatory activities of GL and the chosen chemical. Results We observed that GL extract significantly reduced both LPS-induced ALI and the production of pro-inflammatory factors including TNF-α, IL-6 and IL-1β. Additionally, GL inhibited the binding of Alexa 488-labeled LPS (LPS-488) to the membrane of THP-1 derived macrophages. GL drastically reduce on the expression of TLR4 and the activation of mitogen-activated protein kinases (MAPKs) and nuclear factor-B (NF-κB). Furthermore, molecular docking revealed that Licochalcone A (LicoA) docked into the LPS binding site of TLR4-MD2 complex. MD2-LicoA binding conformation was found to be stable using molecular dynamic simulations. SPRi indicated that LicoA bound to TLR4-MD2 recombinant protein with a KD of 3.87 × 10 −7 M. LicoA dose-dependently reduced LPS-488 binding to the cell membrane. LicoA was found to significantly inhibit LPS-induced lung damage and inflammation. Furthermore, LicoA inhibited TLR4 expression, MAPK and NF-κB activation in a dose-dependent manner. The inhibitory effects of GL and LicoA on LPS-induced inflammation and TLR4 signaling activation were partly eliminated by TLR4 overexpression. Conclusion Our findings imply that GL and LicoA exert inhibitory effects on inflammation by targeting the TLR4 directly.

LicochalconeB inhibits cGAS-STING signaling pathway and prevents autoimmunity diseases

Flavonoids derived from licorice suppress LPS-induced acute lung injury in mice by inhibiting the cGAS-STING signaling pathway

Targeting STING oligomerization with licochalcone D ameliorates STING-driven inflammatory diseases

Lysosomal Control of the Cgas-Sting Signaling.

Licorice extract inhibits the cGAS-STING pathway and protects against non-alcoholic steatohepatitis

cGAS-STING signaling pathway in gastrointestinal inflammatory disease and cancers

Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction

Development of an orally bioavailable covalent STING inhibitor

Radix Glycyrrhizae extract and licochalcone a exert an anti-inflammatory action by direct suppression of toll like receptor 4

Development of small molecule inhibitors/agonists targeting STING for disease

Structural Insights into a Shared Mechanism of Human STING Activation by a Potent Agonist and an Autoimmune Disease-Associated Mutation.

Licochalcone A Inhibits Prostaglandin E2 by Targeting the MAPK Pathway in LPS Activated Primary Microglia

Cyclopeptide Inhibitors Target the N‐Terminal Tail of STING and Alleviate Autoinflammation

CDK inhibitor Palbociclib targets STING to alleviate autoinflammation

STING inhibitors target the cyclic dinucleotide binding pocket

Total glucosides of paeony alleviates cGAS-STING-mediated diseases by blocking the STING-IRF3 interaction

Small molecules targeting cGAS-STING pathway for autoimmune disease

Emerging role of the cGAS-STING signaling pathway in autoimmune diseases: Biologic function, mechanisms and clinical prospection

Intrinsic STING Switches off Pathogenetic Programs of Th1 Cells to Inhibit Colitis

Licochalcone A: a review of its pharmacology activities and molecular mechanisms

Targeting STING oligomerization with small-molecule inhibitors